We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma
Read MoreHide Full Article
Key Takeaways
Veeva Systems unveiled China Campaign Manager to drive omnichannel engagement for local pharma firms.
VEEV enhances campaign execution via personalization, analytics, and integration with its CRM suite.
Veeva Systems deepens its Asia-Pacific foothold as top biopharmas adopt region-specific solutions.
Veeva Systems (VEEV - Free Report) recently launched the Veeva China Campaign Manager, a tailored solution designed to drive precision omnichannel engagement. Built on the widely adopted Veeva CRM platform, this new offering helps pharma companies in China orchestrate compliant campaigns across multiple channels, including face-to-face, email, web, and remote meetings. By optimizing execution with closed-loop analytics and message personalization, Veeva Systems aims to meet the region's unique regulatory and commercial requirements while improving customer experience.
This strategic expansion underscores Veeva Systems’ continued push to localize and innovate its offerings for high-growth international markets. As digital engagement becomes more critical to commercial success in life sciences, Veeva China Campaign Manager offers a scalable path for companies to modernize their go-to-market strategies.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of the company closed flat at $284.58 on Monday. However, in the year-to-date period, VEEV’s shares have gained 34.4% compared with the industry’s 24.6% growth. The S&P 500 increased 1.2% in the same time frame.
The launch of Veeva China Campaign Manager positions VEEV for long-term growth by deepening its footprint in one of the world’s largest pharmaceutical markets. As regulatory-compliant, omnichannel engagement becomes a competitive necessity in China, Veeva Systems’ localized solution offers pharma clients the tools to execute more effective, personalized campaigns. This not only enhances customer retention and platform adoption but also strengthens Veeva Systems’ recurring revenue base and competitive moat in Asia-Pacific.
Meanwhile, VEEV currently has a market capitalization of $46.2 billion. VEEV expects 14.6% growth in its earnings for fiscal 2026.
Image Source: Zacks Investment Research
More on the News
Veeva China Campaign Manager is a specialized solution developed to meet the evolving needs of pharmaceutical companies operating in China’s complex digital and regulatory environment. Built on the widely adopted Veeva China CRM Suite, the tool is designed to enhance campaign execution by providing better coordination between sales and marketing functions. With its integration across both personal and non-personal engagement channels, including WeChat service accounts, WeCom, remote meetings, calls, events, and remote detailing, it enables biopharma companies to effectively reach healthcare professionals (HCPs) through their preferred platforms.
The platform's key features include integrated digital reach for precision targeting via advanced tagging and segmentation, enabling ready-to-use digital engagement channels within the CRM. It supports synchronized planning and execution across field and non-field teams, empowering field reps to adjust HCP target lists, share content, and select communication channels dynamically.
Additional features include customizable surveys to collect feedback, actionable marketing insights that enhance campaign adaptability in real time, and a goal-oriented tracking system that offers a comprehensive view of campaign effectiveness. These capabilities ensure continuous improvement of campaign strategy, channel efficiency, and target reach.
Veeva China Campaign Manager integrates tightly with other Veeva ecosystem products, such as Veeva PromoMats for content management and Veeva Network for master data governance. This integration supports global compliance while enabling localized execution strategies. Already selected by more of the top 20 global biopharmas than any other CRM solution in China, Veeva Systems’ continued investment in region-specific tools like Campaign Manager strengthens its position as a key technology enabler for pharmaceutical commercialization in Asia-Pacific.
VEEV’s Zacks Rank & Other Stocks to Consider
VEEV sports a Zacks Rank #1 (Strong Buy) at present.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma
Key Takeaways
Veeva Systems (VEEV - Free Report) recently launched the Veeva China Campaign Manager, a tailored solution designed to drive precision omnichannel engagement. Built on the widely adopted Veeva CRM platform, this new offering helps pharma companies in China orchestrate compliant campaigns across multiple channels, including face-to-face, email, web, and remote meetings. By optimizing execution with closed-loop analytics and message personalization, Veeva Systems aims to meet the region's unique regulatory and commercial requirements while improving customer experience.
This strategic expansion underscores Veeva Systems’ continued push to localize and innovate its offerings for high-growth international markets. As digital engagement becomes more critical to commercial success in life sciences, Veeva China Campaign Manager offers a scalable path for companies to modernize their go-to-market strategies.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of the company closed flat at $284.58 on Monday. However, in the year-to-date period, VEEV’s shares have gained 34.4% compared with the industry’s 24.6% growth. The S&P 500 increased 1.2% in the same time frame.
The launch of Veeva China Campaign Manager positions VEEV for long-term growth by deepening its footprint in one of the world’s largest pharmaceutical markets. As regulatory-compliant, omnichannel engagement becomes a competitive necessity in China, Veeva Systems’ localized solution offers pharma clients the tools to execute more effective, personalized campaigns. This not only enhances customer retention and platform adoption but also strengthens Veeva Systems’ recurring revenue base and competitive moat in Asia-Pacific.
Meanwhile, VEEV currently has a market capitalization of $46.2 billion. VEEV expects 14.6% growth in its earnings for fiscal 2026.
Image Source: Zacks Investment Research
More on the News
Veeva China Campaign Manager is a specialized solution developed to meet the evolving needs of pharmaceutical companies operating in China’s complex digital and regulatory environment. Built on the widely adopted Veeva China CRM Suite, the tool is designed to enhance campaign execution by providing better coordination between sales and marketing functions. With its integration across both personal and non-personal engagement channels, including WeChat service accounts, WeCom, remote meetings, calls, events, and remote detailing, it enables biopharma companies to effectively reach healthcare professionals (HCPs) through their preferred platforms.
The platform's key features include integrated digital reach for precision targeting via advanced tagging and segmentation, enabling ready-to-use digital engagement channels within the CRM. It supports synchronized planning and execution across field and non-field teams, empowering field reps to adjust HCP target lists, share content, and select communication channels dynamically.
Additional features include customizable surveys to collect feedback, actionable marketing insights that enhance campaign adaptability in real time, and a goal-oriented tracking system that offers a comprehensive view of campaign effectiveness. These capabilities ensure continuous improvement of campaign strategy, channel efficiency, and target reach.
Veeva China Campaign Manager integrates tightly with other Veeva ecosystem products, such as Veeva PromoMats for content management and Veeva Network for master data governance. This integration supports global compliance while enabling localized execution strategies. Already selected by more of the top 20 global biopharmas than any other CRM solution in China, Veeva Systems’ continued investment in region-specific tools like Campaign Manager strengthens its position as a key technology enabler for pharmaceutical commercialization in Asia-Pacific.
VEEV’s Zacks Rank & Other Stocks to Consider
VEEV sports a Zacks Rank #1 (Strong Buy) at present.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.